Skip to main content
Top
Published in: Pituitary 5/2019

01-10-2019 | Pituitary Adenoma

Predictive modeling for pituitary adenomas: single center experience in 501 consecutive patients

Authors: A. L. Pappy II, A. Savinkina, C. Bicknese, S. Neill, N. M. Oyesiku, A. G. Ioachimescu

Published in: Pituitary | Issue 5/2019

Login to get access

Abstract

Background

Personalized postoperative management of patients with pituitary adenomas requires an early risk stratification system.

Methods

We reviewed 501 cases operated between 10/27/2011 and 5/5/2016 by a single neurosurgeon. We determined biochemical remission and tumor resection at 3 months, and biochemical recurrence, tumor recurrence, radiation and reoperation during follow-up. We considered age, gender, tumor diameter, cavernous sinus invasion (CSI) by MRI, diagnostic category (clinical, biochemical and immunohistochemical), and proliferation markers in a Cox proportional hazards model. We built predictive models with the significant parameters and used Kaplan–Meier survival curves for time-dependent analyses.

Results

The 501 cases comprised 141 functional and 360 nonfunctional adenomas. Tumor diameter, CSI, and ki-67 index predicted long-term events. Model 1 (CSI, diameter ≥ 2.9 cm and ki-67 > 3%) identified 18 (3.6%) adenomas and predicted persistent hypersecretory syndrome and residual tumor with 98.7% specificity (OR 8.6; CI 3.0–24.7). Model 2 (ki-67 > 3% and CSI) identified 48 (9.6%) adenomas and had 93.1% specificity (OR 3.3; CI 1.8–6.0). Model 3 (ki-67 > 3%, mitoses and p53, former “atypical” adenoma) identified 26 (5.2%) adenomas and had 96.0% specificity (OR 2.3; CI 1.0–5.0). Model 1 best predicted the long-term event-free survival and was strengthened when Knosp 3–4 CSI grades were used. Model 2 better identified the smaller adenomas at risk. Among the WHO 2017 special PA subtypes, patients with silent corticotroph adenoma had a lower event-free survival than ACTH-negative nonfunctional adenomas.

Conclusion

Use of CSI, ki-67 and tumor diameter in prediction models facilitates tailored surveillance and management of patients with pituitary adenomas.
Literature
1.
go back to reference Ostrom QT, Gittleman H, Farah P et al (2013) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 15(Suppl 2):ii1–ii56PubMedPubMedCentralCrossRef Ostrom QT, Gittleman H, Farah P et al (2013) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 15(Suppl 2):ii1–ii56PubMedPubMedCentralCrossRef
2.
go back to reference Katznelson L, Laws ER, Melmed S et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951PubMedCrossRef Katznelson L, Laws ER, Melmed S et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951PubMedCrossRef
3.
go back to reference Nieman LK, Biller BMK, Findling JW et al (2015) Treatment of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 100(8):2807–2831PubMedPubMedCentralCrossRef Nieman LK, Biller BMK, Findling JW et al (2015) Treatment of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 100(8):2807–2831PubMedPubMedCentralCrossRef
4.
go back to reference Melmed S, Casanueva FF, Hoffman AR et al (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96(2):273–288PubMedCrossRef Melmed S, Casanueva FF, Hoffman AR et al (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96(2):273–288PubMedCrossRef
5.
go back to reference Tampourlou M, Ntali G, Ahmed S et al (2017) Outcome of nonfunctioning pituitary adenomas that regrow after primary treatment: a study from two large UK centers. J Clin Endocrinol Metab 102(6):1889–1897PubMedCrossRef Tampourlou M, Ntali G, Ahmed S et al (2017) Outcome of nonfunctioning pituitary adenomas that regrow after primary treatment: a study from two large UK centers. J Clin Endocrinol Metab 102(6):1889–1897PubMedCrossRef
6.
go back to reference Colao A, Grasso LF, Pivonello R, Lombardi G (2011) Therapy of aggressive pituitary tumors. Expert Opin Pharmacother 12(10):1561–1570PubMedCrossRef Colao A, Grasso LF, Pivonello R, Lombardi G (2011) Therapy of aggressive pituitary tumors. Expert Opin Pharmacother 12(10):1561–1570PubMedCrossRef
7.
go back to reference Di Ieva A, Rotondo F, Syro LV, Cusimano MD, Kovacs K (2014) Aggressive pituitary adenomas-diagnosis and emerging treatments. Nat Rev Endocrinol. 10(7):423–435PubMedCrossRef Di Ieva A, Rotondo F, Syro LV, Cusimano MD, Kovacs K (2014) Aggressive pituitary adenomas-diagnosis and emerging treatments. Nat Rev Endocrinol. 10(7):423–435PubMedCrossRef
8.
go back to reference Lloyd RV, Kovacs K, Young WF Jr, Farrel WE, Asa SL, Trouillas J, Kontogeorgos G, Sano T, Scheithauer BHE (2004) Pituitary tumors: introduction. In: DeLellis RA, Lloyd RV, Heitz PUEC (eds) World Health Organization classification of tumours: pathology and genetics of tumours of endocrine organs, 3rd edn. International Agency for Research and Cancer, Lyon, pp 10–13 Lloyd RV, Kovacs K, Young WF Jr, Farrel WE, Asa SL, Trouillas J, Kontogeorgos G, Sano T, Scheithauer BHE (2004) Pituitary tumors: introduction. In: DeLellis RA, Lloyd RV, Heitz PUEC (eds) World Health Organization classification of tumours: pathology and genetics of tumours of endocrine organs, 3rd edn. International Agency for Research and Cancer, Lyon, pp 10–13
9.
go back to reference Zaidi HA, Cote DJ, Dunn IF, Laws ER (2016) Predictors of aggressive clinical phenotype among immunohistochemically confirmed atypical adenomas. J Clin Neurosci 34:246–251PubMedCrossRef Zaidi HA, Cote DJ, Dunn IF, Laws ER (2016) Predictors of aggressive clinical phenotype among immunohistochemically confirmed atypical adenomas. J Clin Neurosci 34:246–251PubMedCrossRef
10.
go back to reference Chiloiro S, Doglietto F, Trapasso B et al (2015) Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis. Neuroendocrinology 101(2):143–150PubMedCrossRef Chiloiro S, Doglietto F, Trapasso B et al (2015) Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis. Neuroendocrinology 101(2):143–150PubMedCrossRef
11.
go back to reference Clayton RN, Jones PW, Reulen RC et al (2016) Mortality in patients with Cushing’s disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. Lancet Diabetes Endocrinol 4(7):569–576PubMedCrossRef Clayton RN, Jones PW, Reulen RC et al (2016) Mortality in patients with Cushing’s disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. Lancet Diabetes Endocrinol 4(7):569–576PubMedCrossRef
12.
go back to reference Lindholm J, Juul S, Jørgensen JOL et al (2001) Incidence and late prognosis of Cushing’s syndrome: a population-based study. J Clin Endocrinol Metab 86(1):117–123PubMed Lindholm J, Juul S, Jørgensen JOL et al (2001) Incidence and late prognosis of Cushing’s syndrome: a population-based study. J Clin Endocrinol Metab 86(1):117–123PubMed
13.
go back to reference Briceno V, Zaidi HA, Doucette JA et al (2017) Efficacy of transsphenoidal surgery in achieving biochemical cure of growth hormone-secreting pituitary adenomas among patients with cavernous sinus invasion: a systematic review and meta-analysis. Neurol Res 39(5):387–398PubMedCrossRef Briceno V, Zaidi HA, Doucette JA et al (2017) Efficacy of transsphenoidal surgery in achieving biochemical cure of growth hormone-secreting pituitary adenomas among patients with cavernous sinus invasion: a systematic review and meta-analysis. Neurol Res 39(5):387–398PubMedCrossRef
14.
go back to reference Hwang J, Seol HJ, Nam D-H, Lee J-I, Lee MH, Kong D-S (2016) Therapeutic strategy for cavernous sinus-invading non-functioning pituitary adenomas based on the modified Knosp grading system. Brain tumor Res Treat 4(2):63–69PubMedPubMedCentralCrossRef Hwang J, Seol HJ, Nam D-H, Lee J-I, Lee MH, Kong D-S (2016) Therapeutic strategy for cavernous sinus-invading non-functioning pituitary adenomas based on the modified Knosp grading system. Brain tumor Res Treat 4(2):63–69PubMedPubMedCentralCrossRef
15.
go back to reference Osamura RY, Lopes MBS, Grossman A, Kontogeorgos G, Trouillas J (2017) Introduction. In: Lloyd RV, Osamura RY, Klöppel G, Rosai J (eds) World Health Organization classification of tumours of endocrine organs, 4th edn. International Agency for Research and Cancer, Lyon, p 13 Osamura RY, Lopes MBS, Grossman A, Kontogeorgos G, Trouillas J (2017) Introduction. In: Lloyd RV, Osamura RY, Klöppel G, Rosai J (eds) World Health Organization classification of tumours of endocrine organs, 4th edn. International Agency for Research and Cancer, Lyon, p 13
16.
go back to reference Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33(4):610–618PubMed Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33(4):610–618PubMed
17.
go back to reference Akaike H (1974) A new look at the statistical model identification. Springer, New York, pp 215–222 Akaike H (1974) A new look at the statistical model identification. Springer, New York, pp 215–222
18.
go back to reference Hardy J (1969) Transphenoidal microsurgery of the normal and pathological pituitary. Clin Neurosurg 16:185–217PubMedCrossRef Hardy J (1969) Transphenoidal microsurgery of the normal and pathological pituitary. Clin Neurosurg 16:185–217PubMedCrossRef
19.
go back to reference Sarkar S, Philip VJ, Kiran Cherukuri S, Chacko AG, Chacko G (2017) Implications of the World Health Organization definition of atypia on surgically treated functional and non-functional pituitary adenomas. Eur J Neurosurg 159:2179–2186 Sarkar S, Philip VJ, Kiran Cherukuri S, Chacko AG, Chacko G (2017) Implications of the World Health Organization definition of atypia on surgically treated functional and non-functional pituitary adenomas. Eur J Neurosurg 159:2179–2186
20.
go back to reference Tortosa F, Webb SM (2016) Atypical pituitary adenomas: 10 years of experience in a reference centre in Portugal. Neurologia 31(2):97–105PubMedCrossRef Tortosa F, Webb SM (2016) Atypical pituitary adenomas: 10 years of experience in a reference centre in Portugal. Neurologia 31(2):97–105PubMedCrossRef
21.
go back to reference Rutkowski MJ, Alward RM, Chen R et al (2018) Atypical pituitary adenoma: a clinicopathologic case series. J Neurosurg 128(4):1058–1065PubMedCrossRef Rutkowski MJ, Alward RM, Chen R et al (2018) Atypical pituitary adenoma: a clinicopathologic case series. J Neurosurg 128(4):1058–1065PubMedCrossRef
22.
go back to reference Trouillas J, Roy P, Sturm N et al (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126(1):123–135PubMedCrossRef Trouillas J, Roy P, Sturm N et al (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126(1):123–135PubMedCrossRef
23.
go back to reference Braileanu M, Hu R, Hoch MJ et al (2019) Pre-operative MRI predictors of hormonal remission status post pituitary adenoma resection. Clin Imaging 55:29–34PubMedCrossRef Braileanu M, Hu R, Hoch MJ et al (2019) Pre-operative MRI predictors of hormonal remission status post pituitary adenoma resection. Clin Imaging 55:29–34PubMedCrossRef
24.
go back to reference Madsen H, Borges TM, Knox AJ et al (2011) Giant pituitary adenomas. Am J Surg Pathol 35(8):1204–1213PubMedCrossRef Madsen H, Borges TM, Knox AJ et al (2011) Giant pituitary adenomas. Am J Surg Pathol 35(8):1204–1213PubMedCrossRef
25.
go back to reference Del Basso De Caro M, Solari D, Pagliuca F et al (2017) Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients. Neurosurg Rev 40(1):105–114PubMedCrossRef Del Basso De Caro M, Solari D, Pagliuca F et al (2017) Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients. Neurosurg Rev 40(1):105–114PubMedCrossRef
26.
go back to reference Honegger J, Prettin C, Feuerhake F, Petrick M, Schulte-Mönting J, Reincke M (2003) Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. J Neurosurg 99(4):674–679PubMedCrossRef Honegger J, Prettin C, Feuerhake F, Petrick M, Schulte-Mönting J, Reincke M (2003) Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. J Neurosurg 99(4):674–679PubMedCrossRef
27.
28.
go back to reference Mastronardi L, Guiducci A, Spera C, Puzzilli F, Liberati F, Maira G (1999) Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody. J Clin Pathol 52(2):107–111PubMedPubMedCentralCrossRef Mastronardi L, Guiducci A, Spera C, Puzzilli F, Liberati F, Maira G (1999) Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody. J Clin Pathol 52(2):107–111PubMedPubMedCentralCrossRef
29.
go back to reference Fusco A, Zatelli MC, Bianchi A et al (2008) Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas. J Clin Endocrinol Metab 93(7):2746–2750PubMedCrossRef Fusco A, Zatelli MC, Bianchi A et al (2008) Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas. J Clin Endocrinol Metab 93(7):2746–2750PubMedCrossRef
30.
go back to reference Widhalm G, Wolfsberger S, Preusser M et al (2009) Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression. J Neurosurg 111(3):563–571PubMedCrossRef Widhalm G, Wolfsberger S, Preusser M et al (2009) Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression. J Neurosurg 111(3):563–571PubMedCrossRef
31.
go back to reference Tanaka Y, Hongo K, Tada T, Sakai K, Kakizawa Y, Kobayashi S (2003) Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time, patient age, and MIB-1 index. J Neurosurg 98(2):359–365PubMedCrossRef Tanaka Y, Hongo K, Tada T, Sakai K, Kakizawa Y, Kobayashi S (2003) Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time, patient age, and MIB-1 index. J Neurosurg 98(2):359–365PubMedCrossRef
32.
go back to reference Filippella M, Galland F, Kujas M et al (2006) Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin Endocrinol (Oxf) 65(4):536–543CrossRef Filippella M, Galland F, Kujas M et al (2006) Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin Endocrinol (Oxf) 65(4):536–543CrossRef
33.
go back to reference Asioli S, Righi A, Iommi M et al (2019) Validation of a clinicopathological score for the prediction of post-surgical evolution of pituitary adenoma: retrospective analysis on 566 patients from a tertiary care centre. Eur J Endocrinol 180(2):127–134PubMedCrossRef Asioli S, Righi A, Iommi M et al (2019) Validation of a clinicopathological score for the prediction of post-surgical evolution of pituitary adenoma: retrospective analysis on 566 patients from a tertiary care centre. Eur J Endocrinol 180(2):127–134PubMedCrossRef
34.
go back to reference Thapar K, Kovacs K, Scheithauer BW et al (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38(1):99–107PubMedCrossRef Thapar K, Kovacs K, Scheithauer BW et al (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38(1):99–107PubMedCrossRef
35.
go back to reference Mizoue T, Kawamoto H, Arita K, Kurisu K, Tominaga A, Uozumi T (1997) MIB1 immunopositivity is associated with rapid regrowth of pituitary adenomas. Acta Neurochir (Wien) 139(5):426–432CrossRef Mizoue T, Kawamoto H, Arita K, Kurisu K, Tominaga A, Uozumi T (1997) MIB1 immunopositivity is associated with rapid regrowth of pituitary adenomas. Acta Neurochir (Wien) 139(5):426–432CrossRef
36.
go back to reference Gejman R, Swearingen B, Hedley-Whyte ET (2008) Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Hum Pathol 39(5):758–766PubMedCrossRef Gejman R, Swearingen B, Hedley-Whyte ET (2008) Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Hum Pathol 39(5):758–766PubMedCrossRef
37.
go back to reference Matsuyama J (2012) Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables. Neurol Med Chir (Tokyo) 52(8):563–569CrossRef Matsuyama J (2012) Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables. Neurol Med Chir (Tokyo) 52(8):563–569CrossRef
38.
go back to reference Miermeister CP, Petersenn S, Buchfelder M et al (2015) Histological criteria for atypical pituitary adenomas—data from the German pituitary adenoma registry suggests modifications. Acta Neuropathol Commun 3(1):50PubMedPubMedCentralCrossRef Miermeister CP, Petersenn S, Buchfelder M et al (2015) Histological criteria for atypical pituitary adenomas—data from the German pituitary adenoma registry suggests modifications. Acta Neuropathol Commun 3(1):50PubMedPubMedCentralCrossRef
39.
go back to reference Jaffrain-Rea ML, Di Stefano D, Minniti G et al (2002) A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer 9(2):103–113PubMedCrossRef Jaffrain-Rea ML, Di Stefano D, Minniti G et al (2002) A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer 9(2):103–113PubMedCrossRef
40.
go back to reference Pizarro CB, Oliveira MC, Coutinho LB, Ferreira NP (2004) Measurement of Ki-67 antigen in 159 pituitary adenomas using the MIB-1 monoclonal antibody. Braz J Med Biol Res 37(2):235–243PubMedCrossRef Pizarro CB, Oliveira MC, Coutinho LB, Ferreira NP (2004) Measurement of Ki-67 antigen in 159 pituitary adenomas using the MIB-1 monoclonal antibody. Braz J Med Biol Res 37(2):235–243PubMedCrossRef
41.
go back to reference Lelotte J, Mourin A, Fomekong E, Michotte A, Raftopoulos C, Maiter D (2018) Both invasiveness and proliferation criteria predict recurrence of non-functioning pituitary macroadenomas after surgery: a retrospective analysis of a monocentric cohort of 120 patients. Eur J Endocrinol 178:237–246PubMedCrossRef Lelotte J, Mourin A, Fomekong E, Michotte A, Raftopoulos C, Maiter D (2018) Both invasiveness and proliferation criteria predict recurrence of non-functioning pituitary macroadenomas after surgery: a retrospective analysis of a monocentric cohort of 120 patients. Eur J Endocrinol 178:237–246PubMedCrossRef
42.
go back to reference Pei L, Melmed S (1997) Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 11(4):433–441PubMedCrossRef Pei L, Melmed S (1997) Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 11(4):433–441PubMedCrossRef
43.
go back to reference Heaney AP, Horwitz GA, Wang Z, Singson R, Melmed S (1999) Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med 5:1317–1321PubMedCrossRef Heaney AP, Horwitz GA, Wang Z, Singson R, Melmed S (1999) Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med 5:1317–1321PubMedCrossRef
44.
go back to reference Filippella M, Galland F, Kujas M et al (2006) Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin Endocrinol (Oxf) 65:536–543CrossRef Filippella M, Galland F, Kujas M et al (2006) Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin Endocrinol (Oxf) 65:536–543CrossRef
45.
go back to reference Trott G, Ongaratti BR, de Oliveira Silva CB et al (2019) PTTG overexpression in non-functioning pituitary adenomas: correlation with invasiveness, female gender and younger age. Ann Diagn Pathol 41:83–89PubMedCrossRef Trott G, Ongaratti BR, de Oliveira Silva CB et al (2019) PTTG overexpression in non-functioning pituitary adenomas: correlation with invasiveness, female gender and younger age. Ann Diagn Pathol 41:83–89PubMedCrossRef
46.
go back to reference Scheithauer BW, Jaap AJ, Horvath E et al (2000) Clinically silent corticotroph tumors of the pituitary gland. Neurosurgery 47(3):723–729 discussion 729–730 PubMed Scheithauer BW, Jaap AJ, Horvath E et al (2000) Clinically silent corticotroph tumors of the pituitary gland. Neurosurgery 47(3):723–729 discussion 729–730 PubMed
47.
go back to reference Cooper O, Ben-Shlomo A, Bonert V, Bannykh S, Mirocha J, Melmed S (2010) Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes. Horm Cancer 1(2):80–92PubMedPubMedCentralCrossRef Cooper O, Ben-Shlomo A, Bonert V, Bannykh S, Mirocha J, Melmed S (2010) Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes. Horm Cancer 1(2):80–92PubMedPubMedCentralCrossRef
48.
go back to reference Ioachimescu AG, Eiland L, Chhabra VS et al (2012) Silent corticotroph adenomas. Neurosurgery 71(2):296–304PubMedCrossRef Ioachimescu AG, Eiland L, Chhabra VS et al (2012) Silent corticotroph adenomas. Neurosurgery 71(2):296–304PubMedCrossRef
49.
go back to reference Yoo F, Chan C, Kuan E, Bergsneider M, Wang M (2018) Comparison of male and female prolactinoma patients requiring surgical intervention. J Neurol Surg B 79(04):394–400CrossRef Yoo F, Chan C, Kuan E, Bergsneider M, Wang M (2018) Comparison of male and female prolactinoma patients requiring surgical intervention. J Neurol Surg B 79(04):394–400CrossRef
50.
go back to reference Kiseljak-Vassiliades K, Carlson NE, Borges MT et al (2015) Growth hormone tumor histological subtypes predict response to surgical and medical therapy. Endocrine 49(1):231–241PubMedCrossRef Kiseljak-Vassiliades K, Carlson NE, Borges MT et al (2015) Growth hormone tumor histological subtypes predict response to surgical and medical therapy. Endocrine 49(1):231–241PubMedCrossRef
51.
go back to reference Sarkar S, Chacko AG, Chacko G (2015) Clinicopathological correlates of extrasellar growth patterns in pituitary adenomas. J Clin Neurosci 22(7):1173–1177PubMedCrossRef Sarkar S, Chacko AG, Chacko G (2015) Clinicopathological correlates of extrasellar growth patterns in pituitary adenomas. J Clin Neurosci 22(7):1173–1177PubMedCrossRef
52.
go back to reference Todnem N, Ward A, Segar S, Rojiani AM, Rahimi SY (2018) Clinically silent adrenocorticotropic hormone—positive Crooke cell adenoma: case report and review of literature. World Neurosurg 119:197–200PubMedCrossRef Todnem N, Ward A, Segar S, Rojiani AM, Rahimi SY (2018) Clinically silent adrenocorticotropic hormone—positive Crooke cell adenoma: case report and review of literature. World Neurosurg 119:197–200PubMedCrossRef
53.
go back to reference Ceccato F, Regazzo D, Barbot M et al (2018) Early recognition of aggressive pituitary adenomas: a single-centre experience. Acta Neurochir (Wien) 160(1):49–55CrossRef Ceccato F, Regazzo D, Barbot M et al (2018) Early recognition of aggressive pituitary adenomas: a single-centre experience. Acta Neurochir (Wien) 160(1):49–55CrossRef
54.
go back to reference Sav A, Rotondo F, Syro LV, Di Ieva A, Cusimano MD, Kovacs K (2015) Invasive, atypical and aggressive pituitary adenomas and carcinomas. Endocrinol Metab Clin N Am 44(1):99–104CrossRef Sav A, Rotondo F, Syro LV, Di Ieva A, Cusimano MD, Kovacs K (2015) Invasive, atypical and aggressive pituitary adenomas and carcinomas. Endocrinol Metab Clin N Am 44(1):99–104CrossRef
55.
go back to reference Raverot G, Burman P, McCormack A et al (2018) European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 178(1):G1–G24PubMedCrossRef Raverot G, Burman P, McCormack A et al (2018) European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 178(1):G1–G24PubMedCrossRef
56.
go back to reference Heaney A (2014) Management of aggressive pituitary adenomas and pituitary carcinomas. J Neurooncol 117(3):459–468PubMedCrossRef Heaney A (2014) Management of aggressive pituitary adenomas and pituitary carcinomas. J Neurooncol 117(3):459–468PubMedCrossRef
57.
go back to reference Chatzellis E, Alexandraki KI, Androulakis II, Kaltsas G (2015) Aggressive pituitary tumors. Neuroendocrinology 101(2):87–104PubMedCrossRef Chatzellis E, Alexandraki KI, Androulakis II, Kaltsas G (2015) Aggressive pituitary tumors. Neuroendocrinology 101(2):87–104PubMedCrossRef
Metadata
Title
Predictive modeling for pituitary adenomas: single center experience in 501 consecutive patients
Authors
A. L. Pappy II
A. Savinkina
C. Bicknese
S. Neill
N. M. Oyesiku
A. G. Ioachimescu
Publication date
01-10-2019
Publisher
Springer US
Published in
Pituitary / Issue 5/2019
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-019-00982-8

Other articles of this Issue 5/2019

Pituitary 5/2019 Go to the issue